Free tool
FAERS Monitor: Zavesca
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021348 or its brand name (Zavesca, Miglustat). Reports on generic versions are filed under their own applications.
Reports
1,085
Serious
967
89% of reports
Hospitalization
406
Death reported
311
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea163
- death153
- seizure112
- niemann-pick disease97
- weight decreased97
- pneumonia86
- disease progression85
- tremor75
- condition aggravated74
- off label use73
- dysphagia66
- pyrexia61
- epilepsy44
- vomiting44
- convulsion43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 13 |
| 2006 | 11 |
| 2007 | 9 |
| 2008 | 11 |
| 2009 | 6 |
| 2010 | 56 |
| 2011 | 56 |
| 2012 | 86 |
| 2013 | 70 |
| 2014 | 55 |
| 2015 | 89 |
| 2016 | 74 |
| 2017 | 81 |
| 2018 | 83 |
| 2019 | 52 |
| 2020 | 52 |
| 2021 | 115 |
| 2022 | 28 |
| 2023 | 33 |
| 2024 | 27 |
| 2025 | 40 |
| 2026 | 28 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,074 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| niemann-pick diseaseSignal | 97 | 85552.9 | 54062.2 | 1,518,397 |
| epilepsySignal | 44 | 27.9 | 20.9 | 1,116 |
| seizureSignal | 112 | 18.8 | 15.8 | 1,880 |
| convulsionSignal | 43 | 14.6 | 10.9 | 532 |
| disease progressionSignal | 85 | 13.9 | 11.4 | 1,013 |
| dysphagiaSignal | 66 | 13.5 | 10.7 | 753 |
| tremorSignal | 75 | 8.8 | 7.0 | 512 |
| weight decreasedSignal | 97 | 6.7 | 5.6 | 474 |
| pneumoniaSignal | 86 | 5.2 | 4.2 | 288 |
| diarrhoeaSignal | 163 | 4.9 | 4.2 | 517 |
| condition aggravatedSignal | 74 | 4.7 | 3.8 | 216 |
| deathSignal | 153 | 3.4 | 3.0 | 274 |
| pyrexiaSignal | 61 | 3.4 | 2.7 | 104 |
| vomiting | 44 | 1.8 | 1.4 | 16 |
| off label use | 73 | 1.6 | 1.3 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.